Haemonetics Corp. (HAE) 73.56 -0.56

Haemonetics Corp.
(HAE) 73.56 -0.56

Last Trade:	69.61	Day Range:	69.20 - 70.17
Trade Time:	04:05PM	52wk Range:	54.99 - 73.488
Prev. Close:	70.17	Market Cap:	1.76B
Open:	69.20	Div Yield:	0
Volume:	86136	PE:	270
EPS:	2.59

The Latest On HAE

Benzinga's Top Upgrades with Color for May 1, 2012 5/1/12 10:15am

UPDATE: Morgan Stanley Upgrades Haemonetics; Removes PT 5/1/12 8:41am

Pall Corporation Signs Definitive Agreement to Sell its Blood Collection, Filtration and Processing Product Lines to Haemonetics for $550M 4/29/12 12:23pm

ViroPharma Launches Hereditary Angioedema Facebook App 3/29/12 8:06am

ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze with Recombinant Human Hyaluronidase 3/6/12 10:45am

Barrington Research Reiterates Haemonetics Outperform, $73 PT 1/31/12 6:35pm

Morgan Stanley Reports Haemonetics Recovery On Track 1/31/12 9:21am

Earnings Roundup 1/30/12 11:35am

Earnings Scheduled For January 30 1/30/12 5:13am

Sickle Cell Knocks Out NFL Player. Can these Companies Help? 1/4/12 1:41pm

Brean Murray Carret Initiates Buy, $37 PT on ViroPharma 12/22/11 11:01am

Piper Jaffray Maintains Overweight Rating and $25 PT on ViroPharma 12/1/11 8:19am

Benzinga's Top Upgrades with Color for May 1, 2012 5/1/12

UPDATE: Morgan Stanley Upgrades Haemonetics; Removes PT 5/1/12

Pall Corporation Signs Definitive Agreement to Sell its Blood Collection, Filtration and Processing Product Lines to Haemonetics for $550M 4/29/12

ViroPharma Launches Hereditary Angioedema Facebook App 3/29/12

ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze with Recombinant Human Hyaluronidase 3/6/12

Barrington Research Reiterates Haemonetics Outperform, $73 PT 1/31/12

Morgan Stanley Reports Haemonetics Recovery On Track 1/31/12

Earnings Roundup 1/30/12

Earnings Scheduled For January 30 1/30/12

Sickle Cell Knocks Out NFL Player. Can these Companies Help? 1/4/12

Brean Murray Carret Initiates Buy, $37 PT on ViroPharma 12/22/11

Piper Jaffray Maintains Overweight Rating and $25 PT on ViroPharma 12/1/11

Sickle Cell Knocks Out NFL Player. Can these Companies Help? 1/4/12

Haemonetics Hits 52-Week High (HAE) 4/11/11

10 Health Care Stocks With Up to 30% Upside 10/26/10

IVIG Market Update (GIFLF.PK, BAX, HAE) 6/1/10

Benzinga's Top Upgrades with Color for May 1, 2012 5/1/12

UPDATE: Morgan Stanley Upgrades Haemonetics; Removes PT 5/1/12

Barrington Research Reiterates Haemonetics Outperform, $73 PT 1/31/12

Morgan Stanley Reports Haemonetics Recovery On Track 1/31/12

Brean Murray Carret Initiates Buy, $37 PT on ViroPharma 12/22/11

Piper Jaffray Maintains Overweight Rating and $25 PT on ViroPharma 12/1/11

UPDATE: Morgan Keegan Lowers PT on Haemonetics to $63 11/1/11

Morgan Stanley Underweight on Haemonetics 11/1/11

Morgan Keegan Lowers PT on Haemonetics to $63 11/1/11

J.P. Morgan Initiates Coverage on ViroPharma Incorporated 10/4/11

Barrington Upgrades Haemonetics To Outperform, $70 PT 8/3/11

Morgan Stanley Takes a Look at Haemonetics 8/2/11

Trade HAE
NOW!

Partner Headlines

Haemonetics Corp. Reports Operating Results (10-K) 5/22/12

Haemonetics Corp. (HAE) President & CEO Brian Concannon sells 6,500 Shares 5/3/12

4 Stocks Hit 52-Week Highs: Kraft, Comcast 4/30/12

Warner Chilcott, Monster Beverage Among Stocks Up on High Volume Monday 4/30/12

Haemonetics Rev Up, Eyes Acquisition - Analyst Blog 4/30/12

Haemonetics Corp. (HAE) President & CEO Brian Concannon sells 5,000 Shares 3/5/12

Haemonetics Reaffirmed at Neutral - Analyst Blog 3/2/12

Haemonetics Corp. (HAE) President & CEO Brian Concannon sells 5,000 Shares 2/2/12

Haemonetics Beats Estimates - Analyst Blog 1/31/12

Haemonetics Stays Neutral - Analyst Blog 12/14/11

Zacks Sell List Highlights: Foster Wheeler AG, ITT, Spectrum Brands Holdings and Haemonetics - Press Releases 12/9/11

Press Releases

Haemonetics to Present at the Jefferies 2012 Global Healthcare Conference 5/22/12 Newswire

Haemonetics Releases Next Generation of IMPACT® Online Blood Utilization Portal 5/8/12 Newswire

Haemonetics to Present at Bank of America Merrill Lynch 2012 Health Care Conference 5/3/12 Newswire

Haemonetics Changes Timing of Fourth Quarter and Year End Fiscal Year 2012 Webcast: April 30, 2012 at 8:00 am Eastern Time 4/29/12 Newswire

Haemonetics Reports 10% Revenue Growth for Fourth Quarter of Fiscal 2012 and $0.80 Adjusted EPS; Also Establishes Fiscal 2013 Guidance 4/29/12 Newswire

Haemonetics Signs Definitive Agreement To Acquire Hemerus Medical, LLC 4/29/12 Newswire

Haemonetics Signs Definitive Agreement to Acquire Pall Corporation's Blood Collection, Filtration and Processing Product Lines For $551 Million 4/29/12 Newswire

Pall Corporation Signs Definitive Agreement to Sell its Blood Collection, Filtration and Processing Product Lines to Haemonetics for $550 Million 4/29/12 Business Wire

Dyax Corp. to Host First Quarter 2012 Earnings Call and Webcast 4/18/12 Business Wire

Dyax and Eclipse Therapeutics Announce Oncology Antibody License Agreement 4/17/12 Business Wire

Dyax Launches Hereditary Angioedema Genetic Counseling Program to Educate Patients and Family Members about Disease and Inheritance 4/11/12 Business Wire

ViroPharma Provides Update on Status of Citizen Petition Regarding Bioequivalence and Exclusivity for Vancocin® (vancomycin hydrochloride, USP) Capsules 4/10/12 Newswire

Get the latest HAE stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Haemonetics Corp. stock price.

Haemonetics Corp. by YCharts

Haemonetics Corp. (HAE) 73.56 -0.56

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On HAE

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social